4Fuster V,Ryden LE,Cannom DS,et al.ACC/AHA/ESC 2006 guidelines for the manegment of patients with atrial fibrillation,full text a report of the American Colllege of Cardialogey/American Heart Association Task Force on carry out guidelines and the European Society of Cardialogy Committee for Practice Guidelines developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society.Europace,2006,8:651-745.
9Mant J,Hobbs FDR,Fletcher K.Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation(the Bimingham Atrial Fibrillation Treatment of the Aged Study,BAFTA):a randomised controlled trial,Lancet,2007,370:493-503.
10ACTIVE WritingGroup on behalf of the ACTIVE Investigators.Clopidogrel plus aspirin versus oral anticoagulation for atrial fibril|ation in the Atrial Fibrillation Ciopidogrel Trial with Irbesartan for Prevention of Vascular Events:a random ised cont rolled trial.Lancet,2006,367:1903-1912.
6Milliez P,Girerd X, Plouin PF, et al. Evidence for an increased rate of cardiovascular events in patients with primary aldoste- ronism. J Am Coll Cardiol, 2005,45: 1243-1248.
7Huang M, Gai X, Yang X, et al. Functional polymorphiarns in ACE and CYP11B2 genes and atrial fibrillation in patients with hypertensive heart disease. Clln Chem Lab Med, 2009,47: 32- 37.
8Amir O, Amir RE, Paz H, et al. Aldosterone synthase gene polymorphism as a determinant of atrial fibrillation in patients with heart failure. Am J Cardiol, 2008,102 : 326-329.
9ACC/AHA Practice Guidelines.ACC/AHMESC guidelines for the management of patients with atrial fibrillation.Eur Heart J,2001,22 (20): 18.
10Heeringa J, van der Kuip DA, Hofman A,et al. Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. Eur Heart J, 2006,27(8 ) : 949-953.
